Suspension of trading
Calliditas Therapeutics AB Share Price Nasdaq
Stocks
CALT
US13124Q1067
Pharmaceuticals
OTC Markets Traded|
Market Closed -
Nasdaq
21:30:01 20/09/2024 BST
|
5-day change | 1st Jan Change | ||
| 40.00 USD | -0.40% |
|
-.--% | - |
| 1 day | -0.40% |
| 3 years | 15.25 | 43 | |
| 5 years | 10.82 | 43 | |
| 10 years | 10.82 | 43 |
| Manager | Title | Age | Since |
|---|---|---|---|
| Director of Finance/CFO | 49 | 31/07/2017 | |
Lars Stubberud
CTO | Chief Tech/Sci/R&D Officer | 62 | 31/12/2023 |
| Chief Tech/Sci/R&D Officer | - | 28/02/2019 |
| Director | Title | Age | Since |
|---|---|---|---|
Mark Hensley
CHM | Chairman | 43 | - |
Yoshikazu Aoki
BRD | Director/Board Member | - | - |
Masaya Etoh
BRD | Director/Board Member | - | - |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
| -0.40% | -.--% | - | - | 1.16B | ||
| -2.33% | +0.53% | +51.65% | +115.42% | 1,056B | ||
| -1.06% | -1.65% | +42.78% | +69.98% | 645B | ||
| -0.65% | -1.32% | +12.98% | +75.49% | 465B | ||
| -2.66% | -1.87% | +73.13% | +41.15% | 368B | ||
| -0.06% | -3.88% | +34.32% | +39.39% | 335B | ||
| -0.79% | +2.01% | +19.82% | +27.79% | 275B | ||
| -1.19% | -1.21% | +9.82% | +10.61% | 255B | ||
| -0.50% | +3.80% | +49.37% | +56.84% | 229B | ||
| -1.47% | -1.53% | +34.28% | +98.89% | 188B | ||
| Average | -0.80% | -0.18% | +36.46% | +59.51% | 423.98B | |
| Weighted average by Cap. | -1.02% | -0.23% | +39.91% | +71.39% |
Employees
222
Sector
Pharmaceuticals
- Stock Market
- Stocks
- 0A5R Stock
- CALT Stock
Select your edition
All financial news and data tailored to specific country editions
















